COLL
Collegium Pharmaceutical, Inc.
Drug Manufacturers - Specialty & Generic · Healthcare · United States
24.03
close · 2026-10-29
value
93
cheaper than peers93
quality
59
stronger fundamentals59
ranked against
Drug Manufacturers - Specialty & Generic
value
quality
41 peerswide variation
Value inputs
| measure | company | vs peers |
| EV to EBITDA | 3.92× | 98 |
| forward P/E | 3.31× | 89 |
| price to sales | 1.19× | 85 |
| price to book | 2.50× | 59 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | 27.4% | 84 |
| operating margin | 16.0% | 69 |
| revenue growth | 8.9% | 58 |
| debt to equity | 297.6% | 16 |
4 of 4 measures available
Facts
| market cap | $782M |
| free cash flow | $332.6M |
| employees | 423 |
| first trade | 2015-05-07 |
| next earnings | 2026-11-05 |
| fundamentals updated | 2026-08-06 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 1.73 | 1.86 | 1.29 | -0.74 |
| free cash flow | $327.6M | $203.3M | $274.3M | $122.6M |
| net income | $62.9M | $69.2M | $48.2M | -$25.0M |
| revenue | $780.6M | $631.4M | $566.8M | $463.9M |
| unusual items | -$14.8M | -$8.4M | -$23.5M | $0 |